American Heart Association (AHA)

The American Heart Association (AHA) funds cardiovascular medical research, educates consumers on healthy living and fosters appropriate cardiac care in an effort to reduce disability and deaths caused by cardiovascular disease and stroke. The AHA also is a key resource for the latest cardiology science through its journals and annual meeting.

RSS icon
Incoming 2023-2024 American College of Cardiology (ACC) president Hadley Wilson, MD, shares insights on how to create health equity through both ACC programs and hospital grassroots community outreach programs. He outlines four programs his heart hospital is piloting in its community in Charlotte, North Carolina.

How cardiologists can address health disparities in their communities

Incoming 2023-2024 American College of Cardiology president Hadley Wilson, MD, shared insights on how to create health equity through grassroots community outreach programs.

Sahil A. Parikh, MD, Director of Endovascular Services at Columbia University Irving Medical Center and Associate Professor of Medicine at the Columbia University College of Physicians and Surgeons, explained the growing trend or interventional cardiologists treating PAD and CLI. He shares what he thinks is important for cardiology departments to know before expanding expanding their programs in this space.

What do interventional cardiologists need to treat PAD and CLI?

Sahil Parikh, MD, director of endovascular services at Columbia University Irving Medical Center, said treating these patients can be quite challenging. 

PCI

New ACC/AHA/SCAI guidance highlights training requirements for interventional cardiologists

The document, which was designed to help guide both interventional cardiology trainees and program directors, was also endorsed by several other industry societies. 

Bertram Pitt, MD, a professor of medicine emeritus at the University of Michigan School of Medicine, explains the role of sodium–glucose co-transporter-2 (SGLT-2) inhibitors for heart failure (HF). Initially developed to treat diabetes, these drugs have been shown to improve HF outcomes in HF in several large, randomized trials over the past few years, including SOLOIST-WHF, DAPA-HF, EMPEROR-Preserved, and the DELIVER trials. The positive results earned their inclusion in the 2022 AHA/ACC/HFSA Guideline for

What clinical research tells us about sotagliflozin and heart failure

Some SGLT2 inhibitors have been linked to significant improvements in HF outcomes, but what about sotagliflozin? We spoke with Bertram Pitt, MD, to learn more.

AHA President Michelle Albert explains what can be done to boost healthcare equity and diversity in cardiology.

AHA President Michelle Albert on addressing health equity issues in cardiology

American Heart Association President Michelle Albert, MD, talked to us about about how to address health inequities in cardiology departments.

Ajay J. Kirtane, MD, director of the cardiac catheterization laboratories and professor of medicine at NewYork-Presbyterian/Columbia University Irving Medical Center, explains the current trial data on catheter renal denervation to treat drug-resistant hypertension at AHA 2022.

Where renal denervation stands for the treatment of drug-resistant hypertension

Ajay Kirtane, MD, director of the cardiac catheterization laboratories at NewYork-Presbyterian/Columbia University Irving Medical Center, explained the most recent clinical trial data on this topic. 

Surgeons Operating On Patient

AI model predicts risk of post-operative AFib

Post-operative atrial fibrillation was once viewed as a fairly insignificant issue, but more recent research suggests it can increase a patient’s risk of multiple adverse events. 

A key step forward: Researchers ID the genes responsible for CAD

The team hopes its findings can lead to significant progress in the war against fatty plaques.

Displaying 73 - 80 of 180
Design by Adaptive Theme